ポリピッド
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.35 | $0 | — |
| 2025 Q4 | -0.41 | $0 | $0 |
| 2025 Q3 | -0.37 | $0 | $0 |
| 2025 Q2 | -0.78 | $0 | $0 |
| 2025 Q1 | -0.70 | $0 | $0 |
| 2024 Q4 | -1.13 | $0 | — |
| 2024 Q3 |
| -1.22 |
| $0 |
| — |
| 2024 Q2 | -1.25 | $0 | — |